Intuitive Surgical (ISRG) was Reiterated by Leerink Partners to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 700 from a previous price target of $640 . Leerink Partners advised their investors in a research report released on Apr 12, 2016.
Many Wall Street Analysts have commented on Intuitive Surgical. Company shares were Reiterated by Leerink Partners on Apr 12, 2016 to “Outperform”, Firm has raised the Price Target to $ 700 from a previous price target of $640 .Company shares were Reiterated by Stifel on Jan 22, 2016 to “Buy”, Firm has raised the Price Target to $ 640 from a previous price target of $600 .Company shares were Reiterated by Leerink Partners on Jan 14, 2016 to “Outperform”, Firm has raised the Price Target to $ 640 from a previous price target of $600 .
On the company’s financial health, Intuitive Surgical reported $5.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.87 according to the earnings call on Jan 21, 2016. Analyst had a consensus of $5.02. The company had revenue of $676.50 million for the quarter, compared to analysts expectations of $676.68 million. The company’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.92 EPS.
Intuitive Surgical opened for trading at $623.04 and hit $626.92 on the upside on Monday, eventually ending the session at $620.2, with a gain of 0.07% or 0.43 points. The heightened volatility saw the trading volume jump to 2,29,889 shares. Company has a market cap of $23,183 M.
In a different news, on Mar 15, 2016, Colin Morales (SVP Manufacturing & Service Op) sold 4,000 shares at $592.66 per share price. According to the SEC, on Mar 15, 2016, Eric H Halvorson (director) sold 4,438 shares at $593.16 per share price. On Mar 14, 2016, Mark J Meltzer (SVP General Counsel & CCO) sold 12,500 shares at $589.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Intuitive Surgical Inc. designs manufactures and markets da Vinci Surgical Systems and related instruments and accessories. The Company’s da Vinci Surgical System consists of a surgeon’s console a patient-side cart and vision system. The da Vinci Surgical System provides its operating surgeons with control range of motion tissue manipulation and three-dimensional (3-D) high-definition (HD) vision. It allows surgeons to work through the small ports enabled by minimally invasive surgery (MIS) procedures. Its da Vinci Surgery utilizes computational robotic and imaging technologies. The Company has four generations of da Vinci Surgical System: the da Vinci Xi Surgical System the da Vinci Si Surgical System the da Vinci S Surgical System and the standard da Vinci Surgical System. The Company focuses on five surgical specialties: urologic surgery gynecologic surgery general surgery cardiothoracic surgery and head and neck surgery.